Levorphanol: The forgotten opioid

Eric Prommer

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Background: Levorphanol (levo-3-hydroxy-N-methylmorphinan) is a strong opioid that is the only available opioid agonist of the morphinan series. Levorphanol was originally synthesized as a pharmacological alternative to morphine more than 40 years ago. It is considered a step-3 opioid by the World Health Organization (WHO) and has a greater potency than morphine. Analgesia produced by levorphanol is mediated via its interactions with μ, δ, and κ opioid receptors. Levorphanol is also an N-methyl-d-aspartate (NMDA) receptor antagonist. There is evidence that levorphanol may inhibit uptake of norepinephrine and serotonin. Similar to morphine, levorphanol undergoes glucuronidation in the liver, and the glucuronidated products are excreted in the kidney. Levorphanol can be given orally, intravenously, and subcutaneously. Objective: This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this often overlooked step-3 opioid. Conclusion: The long half-life of the drug increases the potential for drug accumulation. Levorphanol has clinical efficacy in neuropathic pain.

Original languageEnglish (US)
Pages (from-to)259-264
Number of pages6
JournalSupportive Care in Cancer
Issue number3
StatePublished - Mar 2007


  • Glucuronidation
  • Levorphanol
  • NMDA
  • Opioids
  • Pain

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Levorphanol: The forgotten opioid'. Together they form a unique fingerprint.

Cite this